Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
AssigneeCuRNA, Inc.
InventorsJoseph COLLARD, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
Claims39
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from at least one modified sugar moiety;
- at least one modified internucleotide linkage;
- at least one modified nucleotide, and combinations thereof;
- wherein said oligonucleotide is an antisense compound which hybridizes to a natural antisense polynucleotide of a Methionine Sulfoxide Reductase A (MSRA) gene and upregulates the function and/or expression of a Methionine Sulfoxide Reductase A (MSRA) gene in vivo or in vitro as compared to a normal control.
(canceled)
(Canceled)
(Canceled)
(canceled)
(canceled)
A method of identifying and selecting at least one oligonucleotide selective for a natural antisense transcript of a MSRA gene as a selected target polynucleotide for in vivo administration comprising:
- identifying at least one oligonucleotide comprising at least five consecutive nucleotides which are at least partially complementary to a polynucleotide that is antisense to the selected target polynucleotide;
- measuring the thermal melting point of a hybrid of an antisense oligonucleotide and the target polynucleotide or the polynucleotide that is antisense to the selected target polynucleotide under stringent hybridization conditions;
- and selecting at least one oligonucleotide for in vivo administration based on the information obtained.
Dependencies are inferred from the claim text.